4.5 Article

Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)

期刊

ARCHIVES OF DISEASE IN CHILDHOOD
卷 96, 期 6, 页码 596-601

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/adc.2010.188946

关键词

-

向作者/读者索取更多资源

Networking is key to overcoming the logistical, methodological and ethical problems related to the implementation of paediatric studies. The adoption of legislation to encourage paediatric clinical trials by the American and European regulatory agencies has opened a new era in the assessment of drug safety and efficacy in children. Two very large international trial networks the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) - have played a critical role in the implementation of this legislation and have facilitated several successful controlled studies on the safety and the efficacy of new and old drugs in paediatric rheumatic diseases. The PRINTO and PRCSG networks can be seen as a model for international co-operation in other paediatric subspecialties.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Rheumatology

Response to: 'Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?' by Fayand et al

Marco Gattorno, Michael Hofer, Federica Vanoni, Silvia Federici, Luca Cantarini, Nicolino Ruperto

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis

Hermine I. Brunner, Chen Chen, Francesca Bovis, Fabrizio De Benedetti, Graciela Espada, Rik Joos, Jonathan Akikusa, Jeffrey Chaitow, Alina Lucica Boteanu, Yukiko Kimura, Christoph Rietschel, Daniel Siri, Elzbieta Smolewska, Heinrike Schmeling, Diane E. Brown, Alberto Martini, Daniel J. Lovell, Bin Huang, Nicolino Ruperto

Summary: Treatment with tocilizumab significantly reduced disability and pain, and improved HRQoL in children with systemic JIA and polyarticular JIA.

ARTHRITIS CARE & RESEARCH (2021)

Article Rheumatology

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study

Pierre Quartier, Ekaterina Alexeeva, Tamas Constantin, Vyacheslav Chasnyk, Nico Wulffraat, Karin Palmblad, Carine Wouters, Hermine Brunner, Katherine Marzan, Rayfel Schneider, Gerd Horneff, Alberto Martini, Jordi Anton, Xiaoling Wei, Alan Slade, Nicolino Ruperto, Ken Abrams

Summary: The study evaluated the efficacy and safety of two canakinumab monotherapy tapering regimens to maintain complete clinical remission in children with systemic JIA. Results showed that reducing canakinumab exposure may be feasible in patients who have achieved clinical remission, but consistent interleukin-1 inhibition is necessary to maintain this response.

ARTHRITIS & RHEUMATOLOGY (2021)

Article Rheumatology

Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis

Gabriella Giancane, Chiara Campone, Maria Francesca Gicchino, Alessandra Alongi, Cecilia Bava, Silvia Rosina, Yaryna Boyko, Neil Martin, Yasser El Miedany, Miroslav Harjacek, Soad Hashad, Maka Ioseliani, Ruben Burgos-Vargas, Rik Joos, Christiaan Scott, Mejbri Manel, Zoilo Morel Ayala, Maria Ekelund, Safiya Al-Abrawi, Maya-Feriel Aiche, Ximena Norambuena, Jose Antonio Melo-Gomes, Nicolino Ruperto, Alessandro Consolaro, Angelo Ravelli

Summary: There is fair concordance between criteria for inactive disease and low disease activity in JIA, with physician and parent global assessments as well as acute-phase reactants being the main drivers of discordance. This highlights the need for further studies to evaluate the impact of subjective perceptions of disease remission and inflammatory activity measures on defining disease activity levels in JIA.

ARTHRITIS CARE & RESEARCH (2021)

Article Rheumatology

Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial

Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Ruben Cuttica, Vladimir Keltsev, Ricardo M. Xavier, Ruben Burgos-Vargas, Inmaculada Calvo Penades, Earl D. Silverman, Graciela Espada, Manuel Ferrandiz Zavaler, Yukiko Kimura, Carolina Duarte, Chantal Job-Deslandre, Rik Joos, Wendy Douglass, Sunethra Wimalasundera, Kamal N. Bharucha, Chris Wells, Daniel J. Lovell, Alberto Martini, Fabrizio de Benedetti

Summary: This study aimed to report the 2-year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (JIA). The results showed high-level disease control for up to 2 years in patients treated with TCZ for polyarticular-course JIA, with a safety profile consistent with previous reports.

ARTHRITIS & RHEUMATOLOGY (2021)

Review Rheumatology

Biological classification of childhood arthritis: roadmap to a molecular nomenclature

Peter A. Nigrovic, Robert A. Colbert, V. Michael Holers, Seza Ozen, Nicolino Ruperto, Susan D. Thompson, Lucy R. Wedderburn, Rae S. M. Yeung, Alberto Martini

Summary: Childhood-onset arthritis is heterogeneous and may share similarities with adult-onset arthritis while also having unique features. The current classification approach has limitations, requiring a new strategy to define biological categories within JIA.

NATURE REVIEWS RHEUMATOLOGY (2021)

Correction Rheumatology

Biological classification of childhood arthritis: roadmap to a molecular nomenclature (Mar, 10.1038/s41584-021-00590-6, 2021)

Peter A. Nigrovic, Robert A. Colbert, V. Michael Holers, Seza Ozen, Nicolino Ruperto, Susan D. Thompson, Lucy R. Wedderburn, Rae S. M. Yeung, Alberto Martini

NATURE REVIEWS RHEUMATOLOGY (2021)

Article Rheumatology

Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial

Paul A. Brogan, Barbara Arch, Helen Hickey, Jordi Anton, Este Iglesias, Eileen Baildam, Kamran Mahmood, Gavin Cleary, Elena Moraitis, Charalampia Papadopoulou, Michael W. Beresford, Phil Riley, Selcan Demir, Seza Ozen, Giovanna Culeddu, Dyfrig A. Hughes, Pavla Dolezalova, Lisa Hampson, John Whitehead, David Jayne, Nicola Ruperto, Despina Eleftheriou

Summary: The study showed that the effectiveness of CYC and MMF treatment for remission induction in childhood PAN is similar, but MMF may be associated with better health-related quality of life. Patients in the MMF group achieved the primary endpoint in a shorter time, with no relapses occurring in either group within 18 months.

ARTHRITIS & RHEUMATOLOGY (2021)

Editorial Material Allergy

Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study

Marta Bustaffa, Francesca Mazza, Diana Sutera, Maria Domenica Carrabba, Maria Alessio, Luca Cantarini, Laura Obici, Donato Rigante, Maria Cristina Maggio, Antonella Insalaco, Gabriele Simonini, Marco Cattalini, Giovanni Conti, Alma Nunzia Olivieri, Patrizia Barone, Angela Miniaci, Valentina Moressa, Maria Greca Magnolia, Luciana Breda, Davide Montin, Alessandra Spagnolo, Giovanna Fabio, Francesca Orlando, Carla Gaggiano, Roberta Mussinelli, Giovanna Capozio, Camilla Celani, Edoardo Marrani, Francesca Ricci, Francesco Calzatini, Maddalena Lancieri, Nicolino Ruperto, Marco Gattorno, Romina Gallizzi

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Article Pediatrics

Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

Athimalaipet Ramanan, Neena Modi, Saskia N. de Wildt

Summary: The COVID-19 pandemic has stimulated new approaches in pediatric clinical research, which Conect4children recommends retaining for future use to improve efficiency, reduce costs, and promote research equity.

PEDIATRIC RESEARCH (2022)

Editorial Material Rheumatology

To Randomize, or Not to Randomize, That is the Question

Nicolino Ruperto, Alberto Martini, Angela Pistorio

ARTHRITIS & RHEUMATOLOGY (2021)

Article Rheumatology

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison

Hermine Brunner, Carlos Abud-Mendoza, Masaaki Mori, Clarissa A. Pilkington, Reema Syed, Syuji Takei, Diego O. Viola, Richard A. Furie, Sandra Navarra, Fengchun Zhang, Damon L. Bass, Gina Eriksson, Anne E. Hammer, Beulah N. Ji, Mohamed Okily, David A. Roth, Holly Quasny, Nicolino Ruperto

Summary: The efficacy and safety of belimumab in treating pediatric and adult patients with systemic lupus erythematosus were found to be consistent in various studies. Patients treated with belimumab showed higher response rates and reduced risk of severe flare compared to those on placebo.

RMD OPEN (2021)

Article Medicine, General & Internal

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Nicolino Ruperto, Hermine Brunner, Olga Synoverska, Tracy Ting, Carlos Abud Mendoza, Alberto Spindler, Yulia Vyzhga, Katherine Marzan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Rita Jerath, Daniel J. Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Yonatan Butbul Aviel, Vyacheslav Chasnyk, Melissa Lerman, Kabita Nanda, Heinrike Schmeling, Heather Tory, Yosef Uziel, Diego O. Viola, Holly B. Posner, Keith S. Kanik, Ann Wouters, Cheng Chang, Richard Zhang, Irina Lazariciu, Ming-Ann Hsu, Ricardo M. Suehiro, Alberto Martini, Daniel J. Lovell

Summary: The trial showed that tofacitinib is an effective treatment for patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections.

LANCET (2021)

Article Rheumatology

The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort

Marta Bustaffa, Isabelle Kone-Paut, Seza Ozen, Gayane Amaryan, Efimia Papadopoulou-Alataki, Romina Gallizzi, Maria Carrabba, Yonatan Butbul Aviel, Luca Cantarini, Maria Alessio, Jordi Anton, Laura Obici, Faysal Gok, Ezgi Deniz Batu, Estefania Moreno, Paul Brogan, Maria Trachana, Gabriele Simonini, Donato Rigante, Yosef Uziel, Antonella Insalaco, Maria Cristina Maggio, Nicolino Ruperto, Marco Gattorno, L. Rossi Semerano

Summary: The new EPCC and INSAID classification of MEFV variants can identify two distinct groups of FMF patients, which differ in clinical characteristics, therapeutic approach, and response to treatment.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2022)

Article Rheumatology

Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis

Chiara Trincianti, Evert Hendrik Pieter Van Dijkhuizen, Alessandra Alongi, Marta Mazzoni, Joost F. Swart, Irina Nikishina, Pekka Lahdenne, Lidia Rutkowska-Sak, Tadej Avcin, Pierre Quartier, Violeta Panaviene, Yosef Uziel, Chris Pruunsild, Veronika Vargova, Soamarat Vilaiyuk, Pavla Dolezalova, Sarah Ringold, Marco Garrone, Nicolino Ruperto, Angelo Ravelli, Alessandro Consolaro

Summary: This study developed and validated new Juvenile Arthritis Disease Activity Score 10 (JADAS10) and clinical JADAS10 (cJADAS10) cutoffs to distinguish different disease activity states in children. Results showed that the cutoffs had good metrologic properties and are suitable for use in clinical trials and routine practice.

ARTHRITIS & RHEUMATOLOGY (2021)

暂无数据